Group 1 - The core point of the article is that the company, Yaoshi Technology, reported a total of 42,961 shareholders as of December 19, 2025 [2]

Group 1 - The core viewpoint of the news is that Yaoshi Technology's stock has seen a slight increase, with a current price of 39.20 yuan per share and a total market capitalization of 9.165 billion yuan [1] - Yaoshi Technology, established on December 26, 2006, and listed on November 10, 2017, is based in Nanjing, Jiangsu Province, and specializes in the research, development, production, and sales of drug molecular building blocks [1] - The company's main business revenue composition includes 83.14% from drug development and commercialization services, 16.72% from drug research services, and 0.14% from other sources [1] Group 2 - Southern Fund's Southern CSI 1000 ETF (512100) is among the top ten circulating shareholders of Yaoshi Technology, having increased its holdings by 230,300 shares in the third quarter, totaling 1.7054 million shares, which represents 0.84% of the circulating shares [2] - The Southern CSI 1000 ETF has achieved a year-to-date return of 29.2%, ranking 1850 out of 4195 in its category, and a one-year return of 24.73%, ranking 2053 out of 4179 [2] - The fund manager of Southern CSI 1000 ETF, Cui Lei, has a total asset scale of 122.76 billion yuan, with the best fund return during the tenure being 207.47% and the worst being -15.93% [3]

Group 1 - The core point of the article is that Ms. Zhou Quan has completed her share reduction plan, selling a total of 400,000 shares of Yaoshi Technology (300725) from September 24 to December 23, which represents 0.17% of the total share capital [1] - The average selling price of the shares was 40.10 yuan, resulting in a significant transaction value [1] - After the reduction, Ms. Zhou's holdings decreased to 5.4491 million shares, which is 2.33% of the total shares, and this reduction does not affect the company's control [1]

证券代码：300725 证券简称：药石科技 公告编号：2025-099 南京药石科技股份有限公司 关于股东减持股份计划实施完成的公告 公司股东周全保证向本公司提供的信息内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 南京药石科技股份有限公司（以下简称"公司"）于 2025 年 9 月 18 日披露了 《关于公司股东减持股份的预披露公告》（公告编号：2025-092）。持有公司股 份 5,849,090 股（占当时剔除已回购股份后总股本比例 2.51%）的股东周全女士 计划在 2025 年 9 月 24 日至 2025 年 12 月 23 日以集中竞价方式或大宗交易方式 减持本公司股份不超过 2,329,600 股，占公司剔除已回购股份后总股本比例 1%。 2025 年 12 月 23 日，公司收到了周全女士出具的《股份减持情况告知函》， 获悉上述减持计划已经实施完毕，根据《上市公司股东减持股份管理暂行办法》 《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指 引第 18 号——股东及董事、高级管理人员减持股 ...

Group 1 - The core point of the article is that the company, Yaoshi Technology (300725), reported that as of December 10, 2025, the number of its shareholders is 43,648 [1]

Core Viewpoint - The company emphasizes its clear medium to long-term development plan, focusing on sustainable development driven by green and intelligent chemical technology innovation [1] Group 1: Development Strategy - The company's key tasks include advancing digitalization and intelligence in management systems [1] - Strengthening compliance systems and scaling up production capacity is a priority [1] - The company aims to accelerate the layout of new molecular businesses such as TIDES and XDC [1] Group 2: Market Adaptation - The company is adapting to changes in the international biopharmaceutical investment environment, which has led to fluctuations in downstream demand [1] - Investment pace has been prudently planned and dynamically adjusted based on market demand, capacity layout, and usage efficiency to maximize shareholder interests [1] - The company will continue to monitor environmental changes and make reasonable arrangements for the use of raised funds [1]

Group 1 - The core viewpoint of the article is that the company, Yaoshi Technology (300725), confirmed that its production and operations are currently normal and there are no undisclosed significant matters [1] Group 2 - The company responded to investor inquiries on an interactive platform, indicating transparency in its operations [1] - The statement reinforces investor confidence by assuring that all major matters have been disclosed [1]

证券日报网讯12月16日，药石科技（300725）在互动平台回答投资者提问时表示，公司股东周全女士股 份减持周期为2025年9月24日至2025年12月23日，截至目前，公司暂未收到其减持完成的书面通知。本 次减持计划实施期间，公司将督促该股东严格遵守相关的法律法规，及时履行信息披露义务。 ...

证券日报网讯12月9日，药石科技（300725）在互动平台回答投资者提问时表示，截至2025年11月28 日，公司股东人数为43297户。 ...

Group 1 - The CRO index experienced a 2% increase during intraday trading, indicating a broad upward trend among constituent stocks [1] - Notable performers included Zhaoyan New Drug, which rose over 9%, and Chengdu Xian Dao, which increased by 6.25% [1] - Other stocks such as Meidi Xi, Yinuosi, and Yaoshi Technology also saw gains, contributing to the overall positive performance of the sector [1]